Press releases
- Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
More ▼
Key statistics
As of last trade Hansa Biopharma AB (0RC7:LSE) traded at 41.92, -24.20% below its 52-week high of 55.30, set on May 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.66 |
---|---|
High | -- |
Low | -- |
Bid | 40.50 |
Offer | 42.56 |
Previous close | 43.22 |
Average volume | 3.26k |
---|---|
Shares outstanding | 63.15m |
Free float | 59.05m |
P/E (TTM) | -- |
Market cap | 2.75bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 20 minutes, as of May 24 2024 12:06 BST.
More ▼